Mehta Mehul, Blume Henning, Beuerle Gerald, Tampal Nilufer, Schug Barbara, Potthast Henrike, Jiang Wenlei, Wilson Clive
U.S. Food and Drug Administration, MD, USA.
SocraTec C&S GmbH, Oberursel, Germany.
Eur J Pharm Sci. 2020 Aug 1;151:105383. doi: 10.1016/j.ejps.2020.105383. Epub 2020 May 27.
The European Federation of Pharmaceutical Sciences (EUFEPS) and American Association of Pharmaceutical Scientists (AAPS) have collaborated since 2015 to organize international conferences to support global harmonization of regulatory requirements for bioequivalence (BE) assessment. This collaboration has resulted in three Global Bioequivalence Harmonization Initiative (GBHI) workshops which provided a unique opportunity for scientists from academia, industry, and regulatory agencies to discuss current, complex BE issues. The 3rd GBHI workshop was held in April 2018 in Amsterdam/The Netherlands and covered the following topics: (a) the necessity of multiple-dose studies in BE testing; (b) BE of transdermal delivery systems, and (c) liposomal parenteral preparations. This report summarizes the extensive discussions that led to better understanding of the similarities and differences across the major regulatory agencies on these topics and paved the way for future international harmonization.
自2015年以来,欧洲药物科学联合会(EUFEPS)和美国药物科学家协会(AAPS)一直合作组织国际会议,以支持生物等效性(BE)评估监管要求的全球协调统一。这种合作促成了三场全球生物等效性协调倡议(GBHI)研讨会,为来自学术界、产业界和监管机构的科学家们提供了一个独特的机会,来讨论当前复杂的生物等效性问题。第三届GBHI研讨会于2018年4月在荷兰阿姆斯特丹举行,涵盖了以下主题:(a)生物等效性测试中多剂量研究的必要性;(b)透皮给药系统的生物等效性;以及(c)脂质体肠胃外制剂。本报告总结了广泛的讨论内容,这些讨论增进了对各主要监管机构在这些主题上异同点的理解,并为未来的国际协调统一铺平了道路。